{'fraction_non_alphanumeric': 0.05053191489361702, 'fraction_numerical': 0.003989361702127659, 'mean_word_length': 5.908256880733945, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Retinoblastoma: What is the future?

Retinoblastoma (RB) predominantly (> 90%) occurs in developing nations (Asia and Africa) with large populations, high birth rates, and low to upper middle per capita gross national incomes (http://datatopics. worldbank.org/world-development-indicators/the-world-by-income-andregion.html).1 From a global perspective, such a skewed demographics distribution of RB portends an unfavorable survival outcomes for these patients. Nevertheless, there are several technological advances and multidisciplinary efforts underway to improve RB outcomes. Future predictions regarding the management of RB can be considered under following subject categories: incidence, therapy, genetic testing, and access to appropriate care.